U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula O4S.Zn
Molecular Weight 161.472
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ZINC SULFATE ANHYDROUS

SMILES

[Zn++].[O-]S([O-])(=O)=O

InChI

InChIKey=NWONKYPBYAMBJT-UHFFFAOYSA-L
InChI=1S/H2O4S.Zn/c1-5(2,3)4;/h(H2,1,2,3,4);/q;+2/p-2

HIDE SMILES / InChI
Molecular Formula O4S
Molecular Weight 96.063
Charge -2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula Zn
Molecular Weight 65.409
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Sources: http://www.npi.gov.au/resource/zinc-and-compounds | https://www.ncbi.nlm.nih.gov/pubmed/27546855 | https://www.ncbi.nlm.nih.gov/pubmed/6353570http://www.chemistrylearner.com/zinc-hydroxide.html | http://www.lookchem.com/Zinc-hydroxide/http://www.azom.com/article.aspx?ArticleID=8415 | https://www.accessdata.fda.gov/scripts/fdcc/?set=IndirectAdditives&id=ZINCSULFIDE | http://www.imse.iastate.edu/files/2014/03/Jianqiang_Li_Master_Thesis.pdf | https://www.ncbi.nlm.nih.gov/pubmed/24477783http://www.t3db.ca/toxins/T3D0733https://www.google.com/patents/US3130034https://www.drugs.com/mtm/zinc-oxide-topical.htmlhttp://www.hmdb.ca/metabolites/HMDB01303http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdfhttps://www.ewg.org/skindeep/ingredient/724913/ZINC_CARBONATE/# | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=582.80 | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=347.10 | https://www.ncbi.nlm.nih.gov/pubmed/10378806 | https://www.ncbi.nlm.nih.gov/pubmed/17633459
Curator's Comment: description was created based on several sources, including http://www.healio.com/news/print/hemonc-today/%7Bfc05fb30-107a-4753-b673-bd0e9b19881d%7D/glucarpidase-in-the-treatment-of-methotrexate-induced-nephrotoxicity

Zinc monocarbonate (Zinc Carbonate) is an inorganic salt. In the United States, Zinc Carbonate may be used as an active ingredient in OTC drug products. When used as an active drug ingredient, the established name is Zinc Carbonate. Zinc monocarbonate is generally recognized as safe by FDA. It is used as skin protectant active ingredient. Zinc carbonate was found to retard the degradation of some poly(lactide-co-glycolide) (PLG) microspheres in vivo and in vitro. Adding Zinc Carbonate is essential during the preparation of PLGA microspheres. It can remarkably improve the stability of drugs in the acid microenvironment inside PLGA microspheres.

CNS Activity

CNS Active
3913
Curator's Comment: Spatial memory deficits in a mouse model of late-onset Alzheimer's disease were caused by Zinc Carbonate supplementation. Long-term dietary administration of zinc ( Zinc Carbonate) can lead to impairments in cognitive function in rats. Microprobe synchrotron X-ray fluorescence (microSXRF) confirmed that brain zinc levels were increased by adding Zinc Carbonate to the drinking water.

Originator

Smithson, R.
38
Curator's Comment: Protherics that initially developed Voraxaze was acquired by BTG International in 2008. After the acquisition BTG International completed the development of Voraxaze and submitted the product for US approval.

Approval Year

1921
1467
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
Activator
1430
Activator
1430
Hydrolytic Enzyme
38
ultraviolet B-induced damage
38
Target ID: ultraviolet B-induced damage
Interacts
323
Activator
1430
Zinc transporter ZIP1
38
Target ID: Q9NY26
Gene ID: 27173.0
Gene Symbol: SLC39A1
Target Organism: Homo sapiens (Human)
Binding Agent
1064
Zinc transporter ZIP2
38
Target ID: Q9NP94
Gene ID: 29986.0
Gene Symbol: SLC39A2
Target Organism: Homo sapiens (Human)
Binding Agent
1064
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Basic research
Unknown

Approved Use

Unknown
Primary
Approved
8429
CORTROPHIN-ZINC

Approved Use

Treatment of ulcerative colitis and other colonic disorders.

Launch Date

-4.55328006E11
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Basic research
Unknown

Approved Use

Unknown
Primary
Basic research
Unknown

Approved Use

Unknown
Secondary
Approved
8429
VORAXAZE

Approved Use

Indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Limitation of use: VORAXAZE is not indicated for use in patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate.

Launch Date

1.32675836E12
Primary
Approved
8429
VUSION

Approved Use

INDICATIONS AND USAGE VUSION Ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal culture for Candida albicans is not adequate evidence of candidal infection since colonization with C. albicans can result in a positive culture. The presence of candidal infection should be established by microscopic evaluation prior to initiating treatment. VUSION Ointment should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes.

Launch Date

1.140048E12
Primary
Approved
8429
ZINC OXIDE

Approved Use

Unknown
Primary
Approved
8429
ZINC SULFATE

Approved Use

Unknown

Launch Date

5.47171205E11
Primary
Phase III
656
ZINC SULFATE

Approved Use

Unknown

Launch Date

5.47171205E11
Primary
Phase III
656
ZINC SULFATE

Approved Use

Unknown

Launch Date

5.47171205E11
PubMed

PubMed

TitleDatePubMed
Topical zinc oxide treatment increases endogenous gene expression of insulin-like growth factor-1 in granulation tissue from porcine wounds.
1994 Dec
Thujaplicin-copper chelates inhibit replication of human influenza viruses.
1998 Aug
Effects of trace metal compounds on HIV-1 reverse transcriptase: an in vitro study.
1999 May
Erythrocyte zinc content in critically ill patients.
2005
Zinc-induced anti-apoptotic effects in SH-SY5Y neuroblastoma cells via the extracellular signal-regulated kinase 1/2.
2005 Apr 27
Increased plasma levels of zinc in obese adult females on a weight-loss program based on a hypocaloric balanced diet.
2005 Nov-Dec
Characterization and inhibition of SARS-coronavirus main protease.
2006
Zinc homeostasis in aging: two elusive faces of the same "metal".
2006 Summer
Assessing toxicity of fine and nanoparticles: comparing in vitro measurements to in vivo pulmonary toxicity profiles.
2007 May
Role of the dissolved zinc ion and reactive oxygen species in cytotoxicity of ZnO nanoparticles.
2010 Dec 15
Quantum dots trigger immunomodulation of the NFκB pathway in human skin cells.
2011 Jul
Glucarpidase rescue in a patient with high-dose methotrexate-induced nephrotoxicity.
2011 Jun
Safety evaluation of sunscreen formulations containing titanium dioxide and zinc oxide nanoparticles in UVB sunburned skin: an in vitro and in vivo study.
2011 Sep
Aerosolized ZnO nanoparticles induce toxicity in alveolar type II epithelial cells at the air-liquid interface.
2012 Feb
Standard molar enthalpy of combustion and formation of quaternary ammonium tetrachlorozincate [n-CnH2n+1 N(CH3)3]2 ZnCl4.
2013 Dec
TiO2, CeO2 and ZnO nanoparticles and modulation of the degranulation process in human neutrophils.
2013 Jul 31
Cytotoxicity in the age of nano: the role of fourth period transition metal oxide nanoparticle physicochemical properties.
2013 Nov 25
Zinc oxide nanoparticles induce migration and adhesion of monocytes to endothelial cells and accelerate foam cell formation.
2014 Jul 1
Immunomodulatory activity of zinc peroxide (ZnO₂) and titanium dioxide (TiO₂) nanoparticles and their effects on DNA and protein integrity.
2014 May 16
Zinc oxide nanoparticles induce apoptosis by enhancement of autophagy via PI3K/Akt/mTOR inhibition.
2014 May 16
Endoplasmic reticulum stress and oxidative stress are involved in ZnO nanoparticle-induced hepatotoxicity.
2015 Apr 2
Effects of zinc fluoride on inhibiting dentin demineralization and collagen degradation in vitro: A comparison of various topical fluoride agents.
2016 Oct 1
Risk Assessment Study of Fluoride Salts: Probability-Impact Matrix of Renal and Hepatic Toxicity Markers.
2016 Sep
Intense 2.7μm emission in Er(3+) doped zinc fluoride glass.
2017 May 15
Patents

Patents

04005147
106
04090844
38
04134847
38
04292237
38
04376079
39
04377675
40
04404196
40
04565693
38
04670586
38
04740363
38
04743435
42
04904401
38
04950702
42
05064815
38
05149745
38
05442047
38
05539121
38
05646324
38
05773011
38
05911978
38
06140331
38
06303833
38
06706904
38
07375243
38
07585885
44
07799339
38
07959530
39
08258190
38
20060128799
38
20060270867
38
20070213331
40
20070249787
39
20080274173
38
20090092554
38
20100048844
38
20100117110
38
20100324259
38
7632959
38
CN105567322
38
EP0119068A1
38
US1767667
38
US20070265374
38
US2522537
38
US2537262
38
US3248354
38
US3453072
38
US3790469
38
US6853140
38

Sample Use Guides

In Vivo Use Guide
Rats: The dosage of zinc fluoride tetrahydrate (ZnF2 •4H2O) was adjusted to contain 2.1 mg (low-dose group, LG), 4.3 mg (mid-dose group, MG), and 5.4 mg fluoride per 200 g rat body weight (high-dose group, HG) corresponding to 5, 10, and 12.5 % of LD50 values for NaF.
Route of Administration: Oral
In Vitro Use Guide
Prepared ground human enamel specimens were immersed in zinc fluoride solutions containing 250 and 750 ppm F- at pH 6 and 4 for 4 min.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:31:55 UTC 2023
Edited
by admin
on Fri Dec 15 15:31:55 UTC 2023
Record UNII
0J6Z13X3WO
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ZINC SULFATE ANHYDROUS
Common Name English
SULFURIC ACID, ZINC SALT (1:1)
Common Name English
NSC-32677
Code English
ZINC SULFATE (ANHYDROUS)
Common Name English
ZINC SULFATE, ANHYDROUS
Common Name English
ZINC SULPHATE ANHYDROUS
Common Name English
ZINC SULFATE [MI]
Common Name English
NSC-135806
Code English
ZINC SULPHATE, ANHYDROUS
Common Name English
ZINC SULFATE [HSDB]
Common Name English
Code System Code Type Description
CHEBI
35176
Created by admin on Fri Dec 15 15:31:55 UTC 2023 , Edited by admin on Fri Dec 15 15:31:55 UTC 2023
PRIMARY
DRUG BANK
DB09322
Created by admin on Fri Dec 15 15:31:55 UTC 2023 , Edited by admin on Fri Dec 15 15:31:55 UTC 2023
PRIMARY
MERCK INDEX
m11629
Created by admin on Fri Dec 15 15:31:55 UTC 2023 , Edited by admin on Fri Dec 15 15:31:55 UTC 2023
PRIMARY Merck Index
NSC
135806
Created by admin on Fri Dec 15 15:31:55 UTC 2023 , Edited by admin on Fri Dec 15 15:31:55 UTC 2023
PRIMARY
RXCUI
1299928
Created by admin on Fri Dec 15 15:31:55 UTC 2023 , Edited by admin on Fri Dec 15 15:31:55 UTC 2023
PRIMARY RxNorm
PUBCHEM
24424
Created by admin on Fri Dec 15 15:31:55 UTC 2023 , Edited by admin on Fri Dec 15 15:31:55 UTC 2023
PRIMARY
HSDB
1063
Created by admin on Fri Dec 15 15:31:55 UTC 2023 , Edited by admin on Fri Dec 15 15:31:55 UTC 2023
PRIMARY
CAS
7733-02-0
Created by admin on Fri Dec 15 15:31:55 UTC 2023 , Edited by admin on Fri Dec 15 15:31:55 UTC 2023
PRIMARY
DAILYMED
0J6Z13X3WO
Created by admin on Fri Dec 15 15:31:55 UTC 2023 , Edited by admin on Fri Dec 15 15:31:55 UTC 2023
PRIMARY
ECHA (EC/EINECS)
231-793-3
Created by admin on Fri Dec 15 15:31:55 UTC 2023 , Edited by admin on Fri Dec 15 15:31:55 UTC 2023
PRIMARY
SMS_ID
100000089121
Created by admin on Fri Dec 15 15:31:55 UTC 2023 , Edited by admin on Fri Dec 15 15:31:55 UTC 2023
PRIMARY
FDA UNII
0J6Z13X3WO
Created by admin on Fri Dec 15 15:31:55 UTC 2023 , Edited by admin on Fri Dec 15 15:31:55 UTC 2023
PRIMARY
NCI_THESAURUS
C75661
Created by admin on Fri Dec 15 15:31:55 UTC 2023 , Edited by admin on Fri Dec 15 15:31:55 UTC 2023
PRIMARY
NSC
32677
Created by admin on Fri Dec 15 15:31:55 UTC 2023 , Edited by admin on Fri Dec 15 15:31:55 UTC 2023
PRIMARY
WIKIPEDIA
Zinc sulfate (medical use)
Created by admin on Fri Dec 15 15:31:55 UTC 2023 , Edited by admin on Fri Dec 15 15:31:55 UTC 2023
PRIMARY
NCI_THESAURUS
C45678
Created by admin on Fri Dec 15 15:31:55 UTC 2023 , Edited by admin on Fri Dec 15 15:31:55 UTC 2023
CONCEPT Industrial Aid
EVMPD
SUB23313
Created by admin on Fri Dec 15 15:31:55 UTC 2023 , Edited by admin on Fri Dec 15 15:31:55 UTC 2023
PRIMARY
EPA CompTox
DTXSID2040315
Created by admin on Fri Dec 15 15:31:55 UTC 2023 , Edited by admin on Fri Dec 15 15:31:55 UTC 2023
PRIMARY
Related Record Type Details
Structure of ZINC SULFATE HEPTAHYDRATE
SOLVATE->ANHYDROUS
Structure of ZINC VALERATE DIHYDRATE
SOLVATE->ANHYDROUS
Structure of ZINC CATION
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of ZINC CATION
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966